XML 98 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
Liabilities for Sales of Future Royalties - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended 49 Months Ended
Jul. 31, 2022
Dec. 31, 2019
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2023
Liability For Sale Of Future Royalties [Line Items]            
Proceeds from the sale of future royalties, net     $ 0 $ 490,950 $ 0  
Non-cash collaboration royalty revenue     $ 69,364 21,692 $ 17,951  
RPI Finance Trust (RPI)            
Liability For Sale Of Future Royalties [Line Items]            
Proceeds from the sale of future royalties, net       0    
OMERS            
Liability For Sale Of Future Royalties [Line Items]            
Proceeds from the sale of future royalties, net       $ 490,950    
Royalty Purchase Agreement            
Liability For Sale Of Future Royalties [Line Items]            
Profit loss sharing percentage on net sales 30.00%          
Royalty Purchase Agreement | RPI Finance Trust (RPI)            
Liability For Sale Of Future Royalties [Line Items]            
Proceeds from sale of future royalties   $ 320,000        
Royalty payment termination description     The agreement with RPI will automatically terminate, and the payment of royalties to RPI will cease, in the event aggregate royalty payments received by RPI are equal to or greater than $608.0 million prior to December 31, 2030, or in the event aggregate royalty payments received by RPI are less than $608.0 million prior to December 31, 2030, or when aggregate royalty payments received by RPI are equal to $800.0 million.      
Royalties transaction costs net   5,800        
Proceeds from the sale of future royalties, net   314,200        
Effective annual interest rate     6.20%     6.20%
Non-cash collaboration royalty revenue           $ 73,400
Royalty Purchase Agreement | OMERS            
Liability For Sale Of Future Royalties [Line Items]            
Proceeds from sale of future royalties $ 500,000          
Royalty payment termination description In July 2022, the Company entered into a Royalty Purchase Agreement with OMERS. Pursuant to the agreement, OMERS paid $500.0 million to the Company in consideration for the right to receive 30% of the future royalty payments due to the Company from KKC based on net sales of Crysvita in the U.S. and Canada under the terms of the KKC Collaboration Agreement. The calculation of royalty payments to OMERS is based on net sales of Crysvita beginning in April 2023 and will expire upon the earlier of the date on which aggregate payments received by OMERS equals $725.0 million or the date the final royalty payment is made to the Company under the KKC Collaboration Agreement.          
Royalty agreement termination threshold amount $ 725,000          
Payment from sale of future royalties 500,000          
Royalties transaction costs net $ 9,100          
Proceeds from the sale of future royalties, net   $ 491,000        
Effective annual interest rate     7.80%     7.80%
Non-cash collaboration royalty revenue           $ 8,600
Royalty Purchase Agreement | Minimum | RPI Finance Trust (RPI)            
Liability For Sale Of Future Royalties [Line Items]            
Royalty agreement termination threshold amount     $ 608,000     608,000
Royalty Purchase Agreement | Maximum | RPI Finance Trust (RPI)            
Liability For Sale Of Future Royalties [Line Items]            
Royalty agreement termination threshold amount     $ 800,000     $ 800,000